Intravenous insulin | Subcutaneous insulin | p Value | |
Dose in first 24 h of insulin treatment (IU) | 54 (36–81) | 34 (17–70) | 0.001 |
Median dose of insulin (IU/24 h) | 55 (33–101) | 46 (20–74) | 0.017 |
Safety | |||
Total no of CBG measurements | 617 | 494 | |
CBG <2.2 mmol/l (percentage of measurements) | 0.2 | 0.2 | 0.844 |
CBG ≤3.3 mmol/l (percentage of measurements) | 5 | 3 | 0.001 |
Efficacy | |||
Study CBG (mmol/l) | 6.0 (5.2–6.3) | 6.4 (5.7–6.9) | 0.044 |
06:00 CBG (mmol/l) | 4.8 (4.3–5.8) | 5.2 (4.5–6.2) | 0.127 |
Percentage of CBG measurements in target range | 41 | 39 | 0.480 |
Percentage of time CBG in target range | 40±14 | 39±14 | 0.511 |
Hyperglycaemic index | 0.9 (0.6–1.6) | 1.0 (0.7–1.7) | 0.836 |
Glycaemic variability (mmol/l) | 2.4 (2.0–3.4) | 2.8 (2.5–3.4) | 0.301 |
CBG, capillary blood glucose.